Phase 2
N=129
Study of Long Term Immune Responses and Safety of the GSK Herpes Zoster Vaccine in Healthy Subjects
Herpes Zoster
Bottom Line
View on ClinicalTrials.gov: NCT01295320 ↗Enrolled (actual)
129
Serious AEs
3.1%
Results posted
Oct 2017
Primary outcome: Primary: Cell-Mediated Immunity (CMI) in Terms of Frequencies of Antigen-specific CD4 T Cells — 726.19; 567.52 cells/million T-cells
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Blood sample (Procedure)
- Age
- Adult, Older Adult · 60+ yrs
- Sex
- All
- Sponsor
- GlaxoSmithKline
- Primary completion
- Jun 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Cell-Mediated Immunity (CMI) in Terms of Frequencies of Antigen-specific CD4 T Cells |
630.76; 473.06 | — |
| PRIMARY Cell-Mediated Immunity (CMI) in Terms of Frequencies of Antigen-specific CD4 T Cells |
630.76; 473.06 | — |
| PRIMARY Cell-Mediated Immunity (CMI) in Terms of Frequencies of Antigen-specific CD4 T Cells |
630.76; 473.06 | — |
| PRIMARY Antigen-specific Antibody (Ab) Concentrations |
7711.3; 2933.4 | — |
| PRIMARY Antigen-specific Antibody (Ab) Concentrations |
7711.3; 2933.4 | — |
| PRIMARY Antigen-specific Antibody (Ab) Concentrations |
7711.3; 2933.4 | — |
| SECONDARY Number of Subjects With Any Serious Adverse Events (SAEs) Related to the Study Participation |
2 | — |
| SECONDARY Number of Subjects With Any SAEs Related to Previous Vaccination and Not Already Documented |
— | — |
| SECONDARY Number of Subjects With Any Fatal SAEs |
2 | — |
| SECONDARY Number of Subjects With Any Suspected Cases of HZ Episodes |
1 | — |
| SECONDARY Number of Subjects With Any Suspected Cases of HZ Episodes Following Participation in 108494 Study and Its Follow-ups (108516, 108518 and 108520) and Not Already Documented |
— | — |
| SECONDARY Number of Subjects and Relationship to Vaccination of Any Potential Immune Mediated Diseases (pIMDs) Following Participation in 108494 Study and Its Follow-ups (108516, 108518 and 108520) and Not Already Documented |
1; 0 | — |
Summary
The subjects included in this study are subjects that participated in study NCT00434577. These subjects were vaccinated with the candidate Herpes Zoster (HZ) vaccine at Month 0 and Month 2 and were then followed at Month 12, Month 24 and Month 36 (study NCT00434577) for safety and immunogenicity.
This long term follow up study (ZOSTER-024 [114825]) will evaluate immune responses to and safety of the previously administered candidate HZ vaccine at Months 48, 60 and 72.
The study visits will be scheduled at approximately one year intervals after the first visit in ZOSTER-024. Blood samples for the evaluation of cellular and humoral immunity will be taken from all subjects at each visit. Information on safety and the occurrence of HZ will also be collected during these visits.
Eligibility Criteria
Inclusion Criteria
- Subjects who the investigator believes can and will comply with the requirements of the protocol
- Previous participation in study NCT00434577 as a member of the intermediate dose active vaccine group
- Written informed consent obtained from the subject
Exclusion Criteria
- Having participated in another study at any time after NCT00434577 study end in which the subject was exposed to an investigational or non-investigational product or; concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product
- Administration of immunoglobulins and/or any blood products within the 3 months preceding the first blood draw
- Having received a vaccine containing some vaccine components, any time after study end of study NCT00434577
- Having received a vaccine against HZ any time after study end of study NCT00434577
- Subject who did not receive a complete vaccination course of 2 doses of the intermediate dose active vaccine in study NCT00434577
Data sourced from ClinicalTrials.gov (NCT01295320). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.